Mineralys Therapeutics CMO Sells Shares Under Trading Plan
I'm PortAI, I can summarize articles.
Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, sold 19,076 shares of common stock on January 13 and 14, 2026, under a Rule 10b5-1 trading plan. The sales were at prices between $31.99 and $32.91, totaling $623,114. After these transactions, Malcom owns 50,437 shares of the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments